Compass Pathways (CMPS) Projected to Release Quarterly Earnings on Tuesday

Key Points

• Compass Pathways is expected to report Q3 2026 results before the market opens on Tuesday, November 3. Analysts forecast a loss of $0.3629 per share; the company previously reported a $1.88-per-share loss, significantly missing estimates.
• Analysts project losses of $1.26 per share for the current fiscal year and $1.87 per share for the next fiscal year.
• Wall Street remains generally bullish: Compass Pathways has a consensus “Moderate Buy” rating and an average price target of $23.36, compared with its recent opening price of $11.05.

Compass Pathways (NASDAQ:CMPS - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.3629) per share for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 2:00 AM ET.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($1.49). On average, analysts expect Compass Pathways to post ($1.26) EPS for the current fiscal year and ($1.87) EPS for the next fiscal year.

Compass Pathways Stock Performance

Shares of NASDAQ CMPS opened at $11.05 on Tuesday. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -2.39 and a beta of 2.55. The stock's fifty day simple moving average is $13.06 and its 200 day simple moving average is $10.29. Compass Pathways has a 52-week low of $4.88 and a 52-week high of $15.87.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CMPS. Stifel Nicolaus lifted their price target on Compass Pathways from $14.00 to $21.00 and gave the stock a "buy" rating in a research note on Tuesday, July 7th. Royal Bank Of Canada reduced their price objective on shares of Compass Pathways from $22.00 to $21.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. Morgan Stanley raised their target price on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. B. Riley Financial lifted their target price on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Finally, BTIG Research boosted their price target on shares of Compass Pathways from $14.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Compass Pathways currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.36.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company's lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.